Work

Failure of Proton Pump Inhibitors to Treat GERD in Neonates and Infants: A Question of Drug, Diagnosis, or Design

Year: 2012

Type: review

Abstract: “The only time you don't fail is the last time you try anything—and it works.” –William Strong Distressful symptoms associated with gastroesophageal reflux constitute a clinical description of gastroesophageal reflux disease, a pathologic condition commonly treated with proton pump inhibitors (PPIs). Despite their pervasive use in neonates and infants, PPIs have not been approved for gastroesophageal reflux disease treatment in this population. This creates a therapeutic conundrum: namely, whether to institute PPI treatment based on knowledge and experience or to withhold it consequent to absence of labeling for young infants. Clinical Pharmacology & Therapeutics (2012); 92 3, 388–392. doi:10.1038/clpt.2012.86

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1038/clpt.2012.86

Authors: V Shakhnovich, R M Ward, G L Kearns

Institutions: Children's Mercy Hospital, University of Missouri–Kansas City, Primary Children's Hospital, University of Utah

Language: English

Topic: Gastroesophageal reflux and treatments

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development